---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000035"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:15:28.900468+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Recursion appoints Najat Khan as Chief R&D and Commercial Officer, joins board

## Summary
- Dr. Khan appointed Chief R&D Officer and Chief Commercial Officer; also elected Class II Director with term through 2026.
- Compensation: base salary $570k, target bonus 50% of base, sign-on bonus $500k, initial equity grant $8M (half RSUs, half options, 4-yr vest).
- Previously Chief Data Science Officer at J&J; will lead R&D and build commercial capabilities at Recursion.
- Board expanded from 8 to 9 members; no related-party transactions requiring disclosure.

## SEC filing metadata
- accession: 0001601830-24-000035
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/0001601830-24-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/rxrx-20240415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000035
- JSON: https://secwatch.observer/filing/0001601830-24-000035.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000035.txt

## Key facts
- Executive change
  Najat Khan was elected as Class II Director at RECURSION PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Class II Director
  source text: increased the number of members of the Board from 8 to 9 and elected Najat Khan, Ph.D., as a Class II Director of the Board, effective April 16, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/0001601830-24-000035-index.htm
- Executive change
  Najat Khan was appointed as Chief Research and Development Officer and Chief Commercial Officer at RECURSION PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Research and Development Officer and Chief Commercial Officer
  source text: On April 16, 2024, the Company announced that Dr. Khan will be its Chief Research and Development Officer and Chief Commercial Officer, effective upon commencement of her employment with the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/0001601830-24-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.